Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2019/09/021436
CTRI/2019/09/021436
Not yet recruiting
Phase 2

A Prospective Study Comparing Induction Chemotherapy Followed By Chemoradiation Versus Chemoradiation Alone In Stage III Non Small Cell Lung Cancer

sskm radiotherapy department0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
sskm radiotherapy department
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
sskm radiotherapy department

Eligibility Criteria

Inclusion Criteria

  • •non small cell lung cancer ecog 2

Exclusion Criteria

  • •small cell lung cancer co morbidities

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
Comparative Study of Treatment Outcome in the Patients suffering from Locally Advanced Esophageal Cancers without any distant metastasis, treated with either Chemotherapy followed by Radiotherapy or Chemotherapy and Radiotherapy Simultaneously.Health Condition 1: null- Locally Advanced Squamous Cell Carcinoma Of Oesophagus.
CTRI/2018/05/013773IPGMER Fluid Research Fund40
Completed
Phase 2
Evaluation of treatment outcome of induction chemotherapy and then Neoadjuvant chemoradiotherapy and surgery in locally advanced rectal cancer
IRCT20200420047139N1Shahid Beheshti University of Medical Sciences30
Active, not recruiting
Phase 1
Comparison of two treatment arms of patients with non-small cell lung cancer. Patients of one arm receive the authorized infusion Durvalumab after chemotherapy, chemotherapy with radiotherapy and optional resection. Patients in the second treatment arm receive Durvalumab from the beginning, in parallel with standard therapy.non-small cell lung cancer stages IIIA (N2) and selected resectable stages IIIBMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2019-000058-77-DEniversity Hospital Essen90
Active, not recruiting
Phase 1
A multi-centre randomised phase II study with a safety run-in of induction chemotherapy followed by capecitabine with or without nelfinavir with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer.
EUCTR2013-004968-56-GBniversity of Oxford Clinical Trials & Research Governance196
Unknown
Phase 2
A Phase II study of induction chemotherapy S-1 and CDDP in patients with FDG-PET positive N2 disease of non-small cell lung cancer.
JPRN-C000000358Fukushima Medical University25